54 research outputs found
Chronic granulomatous disease: the European experience.
CGD is an immunodeficiency caused by deletions or mutations in genes that encode subunits of the leukocyte NADPH oxidase complex. Normally, assembly of the NADPH oxidase complex in phagosomes of certain phagocytic cells leads to a "respiratory burst", essential for the clearance of phagocytosed micro-organisms. CGD patients lack this mechanism, which leads to life-threatening infections and granuloma formation. However, a clear picture of the clinical course of CGD is hampered by its low prevalence (approximately 1:250,000). Therefore, extensive clinical data from 429 European patients were collected and analyzed. Of these patients 351 were males and 78 were females. X-linked (XL) CGD (gp91(phox) deficient) accounted for 67% of the cases, autosomal recessive (AR) inheritance for 33%. AR-CGD was diagnosed later in life, and the mean survival time was significantly better in AR patients (49.6 years) than in XL CGD (37.8 years), suggesting a milder disease course in AR patients. The disease manifested itself most frequently in the lungs (66% of patients), skin (53%), lymph nodes (50%), gastrointestinal tract (48%) and liver (32%). The most frequently cultured micro-organisms per episode were Staphylococcus aureus (30%), Aspergillus spp. (26%), and Salmonella spp. (16%). Surprisingly, Pseudomonas spp. (2%) and Burkholderia cepacia (<1%) were found only sporadically. Lesions induced by inoculation with BCG occurred in 8% of the patients. Only 71% of the patients received antibiotic maintenance therapy, and 53% antifungal prophylaxis. 33% were treated with gamma-interferon. 24 patients (6%) had received a stem cell transplantation. The most prominent reason of death was pneumonia and pulmonary abscess (18/84 cases), septicemia (16/84) and brain abscess (4/84). These data provide further insight in the clinical course of CGD in Europe and hopefully can help to increase awareness and optimize the treatment of these patients
Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.
Few studies have evaluated the impact of pre-treatment drug resistance (PDR) on response to combination antiretroviral treatment (cART) in children. The objective of this joint EuroCoord-CHAIN-EPPICC/PENTA project was to assess the prevalence of PDR mutations and their association with virological outcome in the first year of cART in children.
HIV-infected children <18Â years initiating cART between 1998 and 2008 were included if having at least one genotypic resistance test prior to cART initiation. We used the World Health Organization 2009 resistance mutation list and Stanford algorithm to infer resistance to prescribed drugs. Time to virological failure (VF) was defined as the first of two consecutive HIV-RNAâ>â500 copies/mL after 6Â months cART and was assessed by Cox proportional hazards models. All models were adjusted for baseline demographic, clinical, immunology and virology characteristics and calendar period of cART start and initial cART regimen.
Of 476 children, 88Â % were vertically infected. At cART initiation, median (interquartile range) age was 6.6Â years (2.1-10.1), CD4 cell count 297 cells/mm(3) (98-639), and HIV-RNA 5.2 log10copies/mL (4.7-5.7). Of 37 children (7.8Â %, 95Â % confidence interval (CI), 5.5-10.6) harboring a virus with â„1 PDR mutations, 30 children had a virus resistant to â„1 of the prescribed drugs. Overall, the cumulative Kaplan-Meier estimate for virological failure was 19.8Â % (95Â %CI, 16.4-23.9). Cumulative risk for VF tended to be higher among children harboring a virus with PDR and resistant to â„1 drug prescribed than among those receiving fully active cART: 32.1Â % (17.2-54.8) versus 19.4Â % (15.9-23.6) (Pâ=â0.095). In multivariable analysis, age was associated with a higher risk of VF with a 12Â % reduced risk per additional year (HR 0.88; 95Â %CI, 0.82-0.95; Pâ<â0.001).
PDR was not significantly associated with a higher risk of VF in children in the first year of cART. The risk of VF decreased by 12Â % per additional year at treatment initiation which may be due to fading of PDR mutations over time. Lack of appropriate formulations, in particular for the younger age group, may be an important determinant of virological failure
HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation
The HLA-DRB3/4/5 loci are closely linked to the HLA-DRB1 gene. Mismatches in these
loci occur with a frequency of about 8%â12% in otherwise 10/10 HLA-matched transplant
pairs. There is preliminary evidence that these disparities may associate with increased
acute graft-versus-host disease (GvHD) rates. The aim of this study was to analyze a large
cohort of German patients and their donors for HLA-DRB3/4/5 compatibility and to
correlate the HLA-DRB3/4/5 matching status with the outcome of unrelated
hematopoietic stem cell transplantation (uHSCT). To this end, 3,410 patients and their
respective donors were HLA-DRB3/4/5 and HLA-DPB1 typed by amplicon-based nextgeneration
sequencing (NGS). All patients included received their first allogeneic
transplant for malignant hematologic diseases between 2000 and 2014. Mismatches in
the antigen recognition domain (ARD) of HLA-DRB3/4/5 genes were correlated with
clinical outcome. HLA-DRB3/4/5 incompatibility was seen in 12.5% (n = 296) and 17.8%
(n = 185) of the 10/10 and 9/10 HLA-matched cases, respectively. HLA-DRB3/4/5
mismatches in the ARD associated with a worse overall survival (OS), as shown in
univariate (5-year OS: 46.1% vs. 39.8%, log-rank p = 0.038) and multivariate analyses
[hazard ratio (HR) 1.25, 95% CI 1.02â1.54, p = 0.034] in the otherwise 10/10 HLAmatched
subgroup. The worse outcome was mainly driven by a significantly higher nonrelapse
mortality (HR 1.35, 95% CI 1.05â1.73, p = 0.017). In the 9/10 HLA-matched
cases, the effect was not statistically significant. Our study results suggest that
mismatches within the ARD of HLA-DRB3/4/5 genes significantly impact the outcome
of otherwise fully matched uHSCT and support their consideration upon donor selection in
the future
HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation
The HLA-DRB3/4/5 loci are closely linked to the HLA-DRB1 gene. Mismatches in these
loci occur with a frequency of about 8%â12% in otherwise 10/10 HLA-matched transplant
pairs. There is preliminary evidence that these disparities may associate with increased
acute graft-versus-host disease (GvHD) rates. The aim of this study was to analyze a large
cohort of German patients and their donors for HLA-DRB3/4/5 compatibility and to
correlate the HLA-DRB3/4/5 matching status with the outcome of unrelated
hematopoietic stem cell transplantation (uHSCT). To this end, 3,410 patients and their
respective donors were HLA-DRB3/4/5 and HLA-DPB1 typed by amplicon-based nextgeneration
sequencing (NGS). All patients included received their first allogeneic
transplant for malignant hematologic diseases between 2000 and 2014. Mismatches in
the antigen recognition domain (ARD) of HLA-DRB3/4/5 genes were correlated with
clinical outcome. HLA-DRB3/4/5 incompatibility was seen in 12.5% (n = 296) and 17.8%
(n = 185) of the 10/10 and 9/10 HLA-matched cases, respectively. HLA-DRB3/4/5
mismatches in the ARD associated with a worse overall survival (OS), as shown in
univariate (5-year OS: 46.1% vs. 39.8%, log-rank p = 0.038) and multivariate analyses
[hazard ratio (HR) 1.25, 95% CI 1.02â1.54, p = 0.034] in the otherwise 10/10 HLAmatched
subgroup. The worse outcome was mainly driven by a significantly higher nonrelapse
mortality (HR 1.35, 95% CI 1.05â1.73, p = 0.017). In the 9/10 HLA-matched
cases, the effect was not statistically significant. Our study results suggest that
mismatches within the ARD of HLA-DRB3/4/5 genes significantly impact the outcome
of otherwise fully matched uHSCT and support their consideration upon donor selection in
the future
Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
BACKGROUND: The addition of monoclonal antibody therapy against GD2 to the treatment of high-risk neuroblastoma led to improved responses in patients. Nevertheless, administration of GD2 antibodies against neuroblastoma is associated with therapy-limiting neuropathic pain. This severe pain is evoked at least partially through complement activation on GD2-expressing sensory neurons. METHODS: To reduce pain while maintaining antitumor activity, we have reformatted the approved GD2 antibody ch14.18 into the IgA1 isotype. This novel reformatted IgA is unable to activate the complement system but efficiently activates leukocytes through the FcαRI (CD89). RESULTS: IgA GD2 did not activate the complement system in vitro nor induced pain in mice. Importantly, neutrophil-mediated killing of neuroblastoma cells is enhanced with IgA in comparison to IgG, resulting in efficient tumoricidal capacity of the antibody in vitro and in vivo. CONCLUSIONS: Our results indicate that employing IgA GD2 as a novel isotype has two major benefits: it halts antibody-induced excruciating pain and improves neutrophil-mediated lysis of neuroblastoma. Thus, we postulate that patients with high-risk neuroblastoma would strongly benefit from IgA GD2 therapy
- âŠ